{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:35:50Z","timestamp":1778628950536,"version":"3.51.4"},"reference-count":39,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.3201\/eid2106.141907","type":"journal-article","created":{"date-parts":[[2015,4,29]],"date-time":"2015-04-29T15:09:48Z","timestamp":1430320188000},"page":"1002-1011","source":"Crossref","is-referenced-by-count":23,"title":["Risk Factors for Acquisition of Drug Resistance during Multidrug-Resistant Tuberculosis Treatment, Arkhangelsk Oblast, Russia, 2005\u20132010"],"prefix":"10.3201","volume":"21","author":[{"given":"Sarah E.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Ershova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Vlasova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Nikishova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Tarasova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Platon","family":"Eliseev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey O.","family":"Maryandyshev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor G.","family":"Shemyakin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Kurbatova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Peter","family":"Cegielski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid2106.141907-201505141358-R1","first-page":"6","article-title":"Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva","volume":"\u2022\u2022\u2022","author":"World Health Organization","year":"2011","journal-title":"Organization"},{"key":"key-10.3201\/eid2106.141907-201505141358-R2","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1164\/ajrccm\/148.6_Pt_1.1547","article-title":"Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.","volume":"148","author":"Kennedy","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"key-10.3201\/eid2106.141907-201505141358-R3","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1128\/AAC.33.8.1298","article-title":"Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis.","volume":"33","author":"Heifets","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid2106.141907-201505141358-R4","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1164\/ajrccm.159.3.9807131","article-title":"Once-daily and twice-daily dosing of p-aminosalicylic acid granules.","volume":"159","author":"Peloquin","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.3201\/eid2106.141907-201505141358-R5","first-page":"539","article-title":"Cycloserine: antituberculous activity in vitro and in the experimental animal.","volume":"73","author":"Steenken","year":"1956","journal-title":"Am Rev Tuberc"},{"key":"key-10.3201\/eid2106.141907-201505141358-R6","first-page":"761","article-title":"The antituberculous activity of thioamide in vitro and in the experimental animal (mouse and guinea pig).","volume":"81","author":"Steenken","year":"1960","journal-title":"Am Rev Respir Dis"},{"key":"key-10.3201\/eid2106.141907-201505141358-R7","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1056\/NEJM199309093291108","article-title":"Treatment of multidrug-resistant tuberculosis.","volume":"329","author":"Iseman","year":"1993","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2106.141907-201505141358-R8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1056\/NEJM199302253280802","article-title":"Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin.","volume":"328","author":"Goble","year":"1993","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2106.141907-201505141358-R9","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1086\/517536","article-title":"Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance.","volume":"44","author":"Cox","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2106.141907-201505141358-R10","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/S0140-6736(09)60331-7","article-title":"Epidemiology of antituberculosis drug resistance 2002\u201307: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance.","volume":"373","author":"Wright","year":"2009","journal-title":"Lancet"},{"key":"key-10.3201\/eid2106.141907-201505141358-R11","first-page":"301","article-title":"Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs\u2013worldwide, 2000\u20132004.","volume":"55","author":"Centers for Disease Control and Prevention","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.3201\/eid2106.141907-201505141358-R12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s10096-005-1284-z","article-title":"Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs.","volume":"24","author":"Toungoussova","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key-10.3201\/eid2106.141907-201505141358-R13","doi-asserted-by":"crossref","unstructured":"Eliseev PI, Maryandyshev AO, Nikishova EI, Tarasova IV, Gorina GP, Chryssanthou E, Epidemiological analyses of tuberculosis in Archangelsk, Russia and implementation of a rapid assay for detection of resistance in this high burden setting. Int J Mycobacteriol. 2013;2:103\u20138.","DOI":"10.1016\/j.ijmyco.2013.04.002"},{"key":"key-10.3201\/eid2106.141907-201505141358-R14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.drup.2014.02.003","article-title":"Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data.","volume":"16","author":"Zignol","year":"2013","journal-title":"Drug Resist Updat"},{"key":"key-10.3201\/eid2106.141907-201505141358-R15","first-page":"S194","article-title":"Tuberculosis drug issues: prices, fixed-dose combination products and second-line drugs.","volume":"4","author":"Laing","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.3201\/eid2106.141907-201505141358-R16","doi-asserted-by":"crossref","unstructured":"Gupta R, Cegielski JP, Espinal MA, Henkens M, Kim JY. Lambregts-Van Weezenbeek CS, et al. Increasing transparency in partnerships for health\u2014introducing the Green Light Committee. Trop Med Int Health. 2002;7:970\u20136.12390604","DOI":"10.1046\/j.1365-3156.2002.00960.x"},{"key":"key-10.3201\/eid2106.141907-201505141358-R17","first-page":"9","article-title":"Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis. Geneva","volume":"\u2022\u2022\u2022","author":"World Health Organization","year":"2000","journal-title":"Organization"},{"key":"key-10.3201\/eid2106.141907-201505141358-R18","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.5588\/ijtld.10.0221","article-title":"Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects.","volume":"15","author":"Gammino","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.3201\/eid2106.141907-201505141358-R19","unstructured":"Centers for Disease Control and Prevention. Public health mycobacteriology: a guide for the level III laboratory. Atlanta: The Centers; 1985. p. 159\u201385."},{"key":"key-10.3201\/eid2106.141907-201505141358-R20","first-page":"17","article-title":"Treatment of tuberculosis: guidelines for national programmes. Geneva","volume":"\u2022\u2022\u2022","author":"World Health Organization","year":"2003","journal-title":"Organization"},{"key":"key-10.3201\/eid2106.141907-201505141358-R21","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/cid\/ciu572","article-title":"Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.","volume":"59","author":"Cegielski","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2106.141907-201505141358-R22","first-page":"301","article-title":"Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs\u2014worldwide, 2000\u20132004.","volume":"55","author":"Centers for Disease Control and Prevention","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.3201\/eid2106.141907-201505141358-R23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3201\/eid1303.061400","article-title":"Worldwide emergence of extensively drug-resistant tuberculosis.","volume":"13","author":"Shah","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid2106.141907-201505141358-R24","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1128\/AAC.49.8.3192-3197.2005","article-title":"Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis.","volume":"49","author":"Maus","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid2106.141907-201505141358-R25","unstructured":"Arkhangelsk Oblast Tuberculosis Control Program. Application for a DOTS PLUS pilot project. Green Light Committee. Arkhangelsk (Russia): The Program: 2002."},{"key":"key-10.3201\/eid2106.141907-201505141358-R26","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/S0140-6736(95)90980-X","article-title":"Emergence of fluoroquinolone-resistant tuberculosis in New York City.","volume":"345","author":"Sullivan","year":"1995","journal-title":"Lancet"},{"key":"key-10.3201\/eid2106.141907-201505141358-R27","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/cid\/cis748","article-title":"Acquired resistance to second-line drugs among persons with tuberculosis in the United States.","volume":"55","author":"Ershova","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2106.141907-201505141358-R28","first-page":"1320","article-title":"Mechanisms of drug resistance in Mycobacterium tuberculosis.","volume":"13","author":"Zhang","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.3201\/eid2106.141907-201505141358-R29","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0140-6736(05)17786-1","article-title":"Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study.","volume":"365","author":"Leimane","year":"2005","journal-title":"Lancet"},{"key":"key-10.3201\/eid2106.141907-201505141358-R30","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1378\/chest.117.3.744","article-title":"Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin\/levofloxacin-containing regimens.","volume":"117","author":"Yew","year":"2000","journal-title":"Chest"},{"key":"key-10.3201\/eid2106.141907-201505141358-R31","doi-asserted-by":"publisher","first-page":"e1001300","DOI":"10.1371\/journal.pmed.1001300","article-title":"Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.","volume":"9","author":"Ahuja","year":"2012","journal-title":"PLoS Med"},{"key":"key-10.3201\/eid2106.141907-201505141358-R32","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.1128\/AAC.00506-13","article-title":"Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.","volume":"57","author":"Fillion","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid2106.141907-201505141358-R33","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1378\/chest.124.4.1476","article-title":"Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong.","volume":"124","author":"Yew","year":"2003","journal-title":"Chest"},{"key":"key-10.3201\/eid2106.141907-201505141358-R34","first-page":"286","article-title":"The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals.","volume":"8","author":"Cegielski","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.3201\/eid2106.141907-201505141358-R35","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJM199404283301702","article-title":"The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis.","volume":"330","author":"Weis","year":"1994","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2106.141907-201505141358-R36","first-page":"818","article-title":"Acquisition of drug resistance in multidrug-resistant Mycobacterium tuberculosis during directly observed empiric retreatment with standardized regimens.","volume":"9","author":"Han","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.3201\/eid2106.141907-201505141358-R37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1473-3099(09)70041-6","article-title":"Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis.","volume":"9","author":"Orenstein","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid2106.141907-201505141358-R38","first-page":"430","article-title":"Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control.","volume":"81","author":"World Health Organization","year":"2006","journal-title":"Wkly Epidemiol Rec"},{"key":"key-10.3201\/eid2106.141907-201505141358-R39","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1183\/09031936.05.00111304","article-title":"Drug-susceptibility testing in tuberculosis: methods and reliability of results.","volume":"25","author":"Kim","year":"2005","journal-title":"Eur Respir J"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/21\/6\/14-1907_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T23:21:27Z","timestamp":1732922487000},"score":1,"resource":{"primary":{"URL":"http:\/\/wwwnc.cdc.gov\/eid\/article\/21\/6\/14-1907_article.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"URL":"https:\/\/doi.org\/10.3201\/eid2106.141907","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}